Rosetta Genomics Announces Launch of New Website

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Rosetta Genomics Announces Launch of New Website

PHILADELPHIA, PA and REHOVOT, ISRAEL--(Marketwired - Aug 5, 2013) - Rosetta Genomics Ltd. ( NASDAQ : ROSG ), a leading developer and provider of microRNA-based molecular diagnostics, announces the launch of a newly formatted website featuring an interactive, secure physician web portal customized for ordering molecular diagnostic testing services, enhanced and readily accessible information for investors, improved navigation and an easier communication portal with the Company. The new website can be accessed at www.rosettagenomics.com . 

The physician web portal will connect Rosetta's CAP-accredited, CLIA-certified laboratory seamlessly to physician offices, hospitals and pathology laboratories in a secured electronic environment. 

In addition, the website includes a video entitled, "Cancer of Unknown Primary (CUP), A Patient's Story," which chronicles a patient's compelling journey commencing with a Cancer of Unknown Primary diagnosis and the frustrations and difficulties associated with not knowing his cancer's tissue of origin and then moving forward with a determination of his cancer's origin through the use of the Rosetta Cancer Origin Test ™ , and the patient's clinical and emotional benefits associated with having this critical knowledge. The complete story can be viewed at http://www.rosettagenomics.com/a-patients-story .

"The new website, with its sleek and modern feel, features enhanced content, improved navigation, and an interactive physician portal. Importantly, for patients and physicians the new website more clearly communicates the connection between our corporate brand and the information our tests provide. Our patient story brings to life the real value underlying our work at Rosetta, which is to develop and market innovative technologies that improve patients' lives," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. 

"We are particularly excited about the innovative physician web portal, which allows clinicians to order tests, review status reports and receive patient test results directly from their office, or remotely from mobile devices and tablets. Importantly, the physician web portal will help physicians to provide their patients with personalized treatment options at any time, and from any place. This portal represents an innovative way of doing business which we believe complements the model of modern medical practices and makes for an easy and effective medium for us to service our physician customers," added Mr. Berlin.

About Rosetta Cancer Testing Services (formerly the miRview ® product line) Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com . Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 or toll free (US) 1-888-522-7971.

About Rosetta Genomics Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test™, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta's development of personalized medicine products and services constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact: Rosetta Genomics Ken Berlin President & CEO (609) 419-9000, ext. 1326 investors@rosettagenomics.com Investor Contacts: LHA Anne Marie Fields (212) 838-3777 afields@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 139

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 158

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 71

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 104

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Unleashing Innovations: The Growth of Chronic Venous Insufficiency Treatments

Updated Category News Views 216

Chronic Venous Insufficiency Market Dynamics Chronic venous insufficiency (CVI) is a common public health concern that affects circulation in the lower limbs. Recent projections indicate a remarkable growth trend, expecting a compound annual growth rate (CAGR) of 9.4% from 2025 to 2034. This uptick stems from the advent of groundbreaking therapies and advanced medical...

Continue Reading
BSTR Miner Unveils Smart Contract Mining for All Investors

Updated Category News Views 343

BSTR Miner Introduces Innovative Smart Contract Mining Service BSTR Miner stands out as a premier cloud mining platform, now proudly offering its new smart contract mining service. This revolutionary service aims to streamline the often-complex world of traditional mining by integrating AI-driven dynamic profit optimization, automated contract generation, and elastic...

Continue Reading
UKG Expands Global Presence with New Operations Hub in Ireland

Updated Category News Views 256

UKG Expands Its Presence in Ireland UKG, a leading provider of HR, payroll, workforce management, and culture solutions, has unveiled plans for its new Global Operations Hub in Kilkenny, Ireland. This exciting initiative includes the creation of around 200 new jobs, primarily focusing on cybersecurity. This move reflects UKG's dedication to expanding its operations and...

Continue Reading
Cathie Wood's Bold Moves: Selling Off Block and Moderna Shares

Updated Category News Views 162

Cathie Wood's Strategic Moves with Ark Invest Cathie Wood, the founder and CEO of Ark Invest, is known for her bold investment strategies, especially concerning innovative companies. Recently, her firm made notable trades with Block Inc and Moderna, hinting at her current viewpoint in the fast-evolving investment landscape. Significant Trade with Block Inc In the last...

Continue Reading
Eurocastle Highlights Leadership Share Transactions and Vision

Updated Category News Views 132

Eurocastle Investment Limited Announces Key Share Transactions EUROCASTLE INVESTMENT LIMITED Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Nicole Barnes Tel: +44 1481 752957 Eurocastle announces Director/PDMR Dealing Notification In line with obligations under relevant regulations, Eurocastle Investment Limited has shared significant updates...

Continue Reading